TickerFacts.

Humacyte, Inc. (HUMA): Long-Term Debt

Annual figures by period end, from SEC filings.

$35.44M
As of 2025-12-31
$36.32M
As of 2026-06-30
2021-12-31: $30.00M2024-12-31: $02025-12-31: $35.44M$35.44M
2021-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$35.44Mn/a2026-03-27, Balance as of period end
2024-12-31$0n/a2026-03-27, Balance as of period end
No annual figure between 2021-12-31 and 2024-12-31.
2021-12-31$30.00Mn/a2022-03-29, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Humacyte, Inc. (HUMA)2025-12-31$35.44Mn/a
TScan Therapeutics, Inc. (TCRX)2025-12-31$32.53M+1.4%
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
AIM ImmunoTech Inc. (AIM)2025-12-31$4.48M+59.5%
Inmune Bio, Inc. (INMB)2024-12-31$15.00Mn/a
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%

Compare HUMA, TCRX, ALEC, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗